Ludmila Kryzhanovskaya

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Indianapolis, Indiana 46285 6156, USA
    J Child Adolesc Psychopharmacol 22:157-65. 2012
  2. ncbi A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285 6156, USA
    J Clin Psychiatry 67:933-45. 2006
  3. ncbi The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 6156, USA
    J Clin Psychiatry 70:247-58. 2009
  4. doi Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial
    Ludmila Kryzhanovskaya
    Eli Lilly and Company
    J Am Acad Child Adolesc Psychiatry 48:60-70. 2009
  5. ncbi Olanzapine versus placebo in the treatment of adolescents with bipolar mania
    Mauricio Tohen
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Am J Psychiatry 164:1547-56. 2007
  6. doi A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychopharmacol 31:349-55. 2011
  7. ncbi Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study
    Mauricio Tohen
    Lilly Research Laboratories, 450 South Madison Ave, Indianapolis, IN 46225, USA
    J Clin Psychiatry 69:1776-89. 2008
  8. ncbi Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics
    Thomas A Hardy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:405-8. 2006
  9. doi Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies
    Mosun Ayan-Oshodi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 32:408-11. 2012
  10. ncbi Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007

Detail Information

Publications14

  1. doi Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Indianapolis, Indiana 46285 6156, USA
    J Child Adolesc Psychopharmacol 22:157-65. 2012
    ..The purpose of these analyses was to compare the weight and other metabolic changes between adolescents and adults during long-term (at least 24 weeks) olanzapine treatment...
  2. ncbi A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285 6156, USA
    J Clin Psychiatry 67:933-45. 2006
    ..Although antipsychotics may be efficacious in this population, elderly patients with dementia may be particularly vulnerable to adverse events. This article reviews the safety of olanzapine in elderly patients with dementia...
  3. ncbi The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 6156, USA
    J Clin Psychiatry 70:247-58. 2009
    ..To describe the safety of olanzapine treatment in adolescents (aged 13-17 years) with schizophrenia or bipolar I disorder, and to compare these data with those of olanzapine-treated adults...
  4. doi Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial
    Ludmila Kryzhanovskaya
    Eli Lilly and Company
    J Am Acad Child Adolesc Psychiatry 48:60-70. 2009
    ..To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia...
  5. ncbi Olanzapine versus placebo in the treatment of adolescents with bipolar mania
    Mauricio Tohen
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Am J Psychiatry 164:1547-56. 2007
    ..The purpose of this study was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed episodes associated with bipolar disorder in adolescents...
  6. doi A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychopharmacol 31:349-55. 2011
    ..Additional efficacy, safety, and tolerability testing are needed...
  7. ncbi Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study
    Mauricio Tohen
    Lilly Research Laboratories, 450 South Madison Ave, Indianapolis, IN 46225, USA
    J Clin Psychiatry 69:1776-89. 2008
    ..To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria)...
  8. ncbi Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics
    Thomas A Hardy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:405-8. 2006
    ..Although interpretation of this study is limited by the cross-sectional study design, it provides additional insight concerning the relationship between antipsychotic use and plasma lipid parameters in this population...
  9. doi Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies
    Mosun Ayan-Oshodi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 32:408-11. 2012
    ..There were no clinically significant changes in electroencephalograms in subjects receiving LY2140023 (n = 26). LY2140023 was generally well tolerated in healthy subjects...
  10. ncbi Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007
    ..09 +/- 1.11; chlorpromazine, 0.72 +/- 2.04; P = 0.042). This analysis suggests that, compared with chlorpromazine, olanzapine may be more efficacious and have a more favorable tolerability profile in treating patients with schizophrenia...
  11. ncbi Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
    Ilya Lipkovich
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
    Psychopharmacol Bull 42:23-39. 2009
    ..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient...
  12. ncbi Diabetes mellitus and antipsychotic treatment in the United Kingdom
    Christopher Carlson
    Eli Lilly and Company, Indianapolis, IN, USA
    Eur Neuropsychopharmacol 16:366-75. 2006
    ..This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics...
  13. doi Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 192:135-43. 2008
    ..Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania...
  14. ncbi Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials
    Patrizia A Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 67:107-13. 2006
    ..The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder...